Cargando…

Efficacy and Tolerability of Telaprevir for Chronic Hepatitis Virus C Genotype 1 Infection: A Meta-Analysis

BACKGROUND: Chronic hepatitis C virus (HCV) infection is one of the leading causes of hepatic cirrhosis and hepatocellular carcinoma, and HCV genotype 1 is the most prevalent genotype and is resistant to current standard therapy. We performed this meta-analysis to evaluate the efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Yuan, Wang, Xiaoping, Shang, Yushu, Schroder, Paul M., Liang, Wenhua, Ling, Xiaoting, Guo, Zhiyong, He, Xiaoshun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527389/ https://www.ncbi.nlm.nih.gov/pubmed/23284915 http://dx.doi.org/10.1371/journal.pone.0052158

Ejemplares similares

Performance of Polymerase Chain Reaction Techniques Detecting Perforin in the Diagnosis of Acute Renal Rejection: A Meta-Analysis
por: Shang, Yushu, et al.
Publicado: (2012)

Calcineurin-Inhibitor Minimization in Liver Transplant Patients with Calcineurin-Inhibitor-Related Renal Dysfunction: A Meta-Analysis
por: Kong, Yuan, et al.
Publicado: (2011)

Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir
por: De Meyer, Sandra, et al.
Publicado: (2014)

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
por: Cooper, Curtis L, et al.
Publicado: (2012)

Telaprevir
Publicado: (2012)

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C
por: Hayashi, N, et al.
Publicado: (2012)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
por: Thorlund, Kristian, et al.
Publicado: (2012)

Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2013)

Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C
por: Brogan, Anita J., et al.
Publicado: (2014)

Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection
por: Yamada, I, et al.
Publicado: (2012)

Efficacy and tolerability of telaprevir (TVR)-based triple therapy in HIV/HCV-coinfected patients
por: De Los Santos, Ignacio, et al.
Publicado: (2014)

Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C
por: Yamagiwa, Satoshi, et al.
Publicado: (2017)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
por: Gomes, Lenyta Oliveira, et al.
Publicado: (2018)

Treatment of genotype one hepatitis C virus (HCV) infection in HIV co-infected patients using telaprevir based regimen
por: Siraj, Dawd S., et al.
Publicado: (2014)

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
por: Colombo, M, et al.
Publicado: (2014)

Outcomes of Technical Variant Liver Transplantation versus Whole Liver Transplantation for Pediatric Patients: A Meta-Analysis
por: Ye, Hui, et al.
Publicado: (2015)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir
por: D’Ambrosio, Roberta, et al.
Publicado: (2012)

Chronic Hepatitis C Therapy in Liver Cirrhosis Complicated by Telaprevir-Induced DRESS
por: Mousa, Omar Y. S., et al.
Publicado: (2014)

Telaprevir Experience From Turkey
por: Komur, Suheyla, et al.
Publicado: (2015)

Cutaneous Eruption due to Telaprevir
por: Falcão, Eduardo Mastrangelo Marinho, et al.
Publicado: (2015)

Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection
por: Bichoupan, Kian, et al.
Publicado: (2017)

Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients
por: Abe, Hiroshi, et al.
Publicado: (2014)

Telaprevir or boceprevir for hepatitis C treatment: a first survey on pharmacoutilization
por: Capuozzo, Maurizio, et al.
Publicado: (2013)

Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C
por: Kondo, C, et al.
Publicado: (2016)

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy
por: Neukam, Karin, et al.
Publicado: (2015)

Comment to “Telaprevir Experience From Turkey”
por: Akar, Tarik, et al.
Publicado: (2015)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

Feasibility of Telaprevir-Based Triple Therapy in Liver Transplant Patients with Hepatitis C Virus: SVR 24 Results
por: Werner, Christoph R., et al.
Publicado: (2013)

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
por: Kieffer, Tara L., et al.
Publicado: (2012)

Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the telaprevir early access program in patients from Romania
por: Streinu-Cercel, Adrian, et al.
Publicado: (2013)

Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
por: Coppola, Nicola, et al.
Publicado: (2014)

Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study
por: Flamm, Steven L., et al.
Publicado: (2014)

Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with Telaprevir
por: Thomas, Xiomara V., et al.
Publicado: (2012)

Impact of Specialty Pharmacy on Telaprevir-Containing 3-Drug Hepatitis C Regimen Persistence
por: Henderson, Rochelle R., et al.
Publicado: (2014)

Anti-rods/rings autoantibody seropositivity does not affect response to telaprevir treatment for chronic hepatitis C infection
por: Calise, S. John, et al.
Publicado: (2016)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
por: Flisiak, Robert, et al.
Publicado: (2016)

Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b
por: Toyota, J, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ngbmi271200d8j2195f431d7me